CY1120176T1 - Μεθοδος για τη μειωση των συμπτωματων που μοιαζουν με αυτα της γριπης που συνδεονται με ενδομυϊκη χορηγηση ιντερφερονης με τη χρηση ενος σχηματος κλιμακουμενης δοσολογιας ταχειας τιτλοδοτησης - Google Patents

Μεθοδος για τη μειωση των συμπτωματων που μοιαζουν με αυτα της γριπης που συνδεονται με ενδομυϊκη χορηγηση ιντερφερονης με τη χρηση ενος σχηματος κλιμακουμενης δοσολογιας ταχειας τιτλοδοτησης

Info

Publication number
CY1120176T1
CY1120176T1 CY20181100424T CY181100424T CY1120176T1 CY 1120176 T1 CY1120176 T1 CY 1120176T1 CY 20181100424 T CY20181100424 T CY 20181100424T CY 181100424 T CY181100424 T CY 181100424T CY 1120176 T1 CY1120176 T1 CY 1120176T1
Authority
CY
Cyprus
Prior art keywords
week
interferon
therapeutically effective
effective dose
administration
Prior art date
Application number
CY20181100424T
Other languages
Greek (el)
English (en)
Inventor
Aaron Deykin
Original Assignee
Biogen Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.
Publication of CY1120176T1 publication Critical patent/CY1120176T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
CY20181100424T 2011-03-15 2018-04-23 Μεθοδος για τη μειωση των συμπτωματων που μοιαζουν με αυτα της γριπης που συνδεονται με ενδομυϊκη χορηγηση ιντερφερονης με τη χρηση ενος σχηματος κλιμακουμενης δοσολογιας ταχειας τιτλοδοτησης CY1120176T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161452807P 2011-03-15 2011-03-15
US201161476930P 2011-04-19 2011-04-19
PCT/US2012/029201 WO2012125809A1 (en) 2011-03-15 2012-03-15 Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Publications (1)

Publication Number Publication Date
CY1120176T1 true CY1120176T1 (el) 2018-12-12

Family

ID=46045072

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100424T CY1120176T1 (el) 2011-03-15 2018-04-23 Μεθοδος για τη μειωση των συμπτωματων που μοιαζουν με αυτα της γριπης που συνδεονται με ενδομυϊκη χορηγηση ιντερφερονης με τη χρηση ενος σχηματος κλιμακουμενης δοσολογιας ταχειας τιτλοδοτησης

Country Status (25)

Country Link
US (6) US9198955B2 (https=)
EP (1) EP2686002B1 (https=)
JP (2) JP6279905B2 (https=)
KR (1) KR102050339B1 (https=)
CN (1) CN103702680A (https=)
AU (1) AU2012229104B2 (https=)
BR (1) BR112013023609A8 (https=)
CA (1) CA2846786C (https=)
CY (1) CY1120176T1 (https=)
DK (1) DK2686002T3 (https=)
EA (1) EA028448B1 (https=)
ES (1) ES2666850T3 (https=)
HR (1) HRP20180621T1 (https=)
HU (1) HUE036931T2 (https=)
IL (1) IL228425A (https=)
LT (1) LT2686002T (https=)
MX (1) MX359947B (https=)
PL (1) PL2686002T3 (https=)
PT (1) PT2686002T (https=)
RS (1) RS57175B1 (https=)
SG (1) SG193446A1 (https=)
SI (1) SI2686002T1 (https=)
SM (1) SMT201800221T1 (https=)
WO (1) WO2012125809A1 (https=)
ZA (1) ZA201306933B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2686002B1 (en) * 2011-03-15 2018-01-24 Biogen Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
EP3092305B1 (en) * 2014-01-09 2023-08-02 Kyushu University, National University Corporation Method of producing microglial cells
US11266344B2 (en) 2016-09-21 2022-03-08 Samsung Electronics Co., Ltd. Method for measuring skin condition and electronic device therefor
WO2022069250A1 (en) * 2020-09-30 2022-04-07 Koninklijke Philips N.V. Methods and systems for performing dose titration

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
DE3273787D1 (en) 1981-02-04 1986-11-20 Japan Found Cancer Human interferon-beta gene
US4695543A (en) 1982-03-23 1987-09-22 Bristol-Myers Company Alpha Interferon GX-1
CA1302320C (en) 1984-06-11 1992-06-02 Hideo Niwa Expression of human cromosomal interferon-_ in animal cells
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
FI90990C (fi) 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
EP0205404B1 (en) 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US5641656A (en) 1993-10-22 1997-06-24 University Of Connecticut Nucleic acids encoding avian interferon (IFN) proteins and recombinant methods using them
TR199901968T2 (xx) * 1996-12-24 1999-12-21 Biogen, Inc. Sabit s�v� interferon form�lleri.
JP2001104482A (ja) * 1999-10-07 2001-04-17 Terumo Corp ２室型プレフィルドシリンジ
EP1605992B1 (en) * 2003-01-30 2018-11-21 Becton, Dickinson and Company Holder with safety shield for a drug delivery device
JP4988562B2 (ja) * 2004-06-01 2012-08-01 アレス トレーディング ソシエテ アノニム 安定化したインターフェロン液体製剤
US20060089593A1 (en) * 2004-10-26 2006-04-27 Sergio Landau Needle-free injection device for individual users
EP1923085A1 (en) * 2006-11-17 2008-05-21 Sanofi-Aventis Deutschland GmbH Dosing and drive mechanism for drug delivery device
CA2672284C (en) * 2006-12-18 2014-08-26 Altus Pharmaceuticals Inc. Human growth hormone formulations
US9044378B2 (en) * 2007-05-31 2015-06-02 Safety Syringes, Inc. Anti-needle stick safety device or system for use with drugs requiring reconstitution
JP5549048B2 (ja) * 2007-08-16 2014-07-16 味の素株式会社 薬剤バイアルとプレフィルドシリンジの接続構造
JP2012530721A (ja) * 2009-06-18 2012-12-06 ワイス・エルエルシー 小モジュール免疫薬のための凍結乾燥製剤
EP2686002B1 (en) * 2011-03-15 2018-01-24 Biogen Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Also Published As

Publication number Publication date
DK2686002T3 (en) 2018-04-30
ZA201306933B (en) 2016-07-27
BR112013023609A2 (pt) 2016-12-06
US20220280610A1 (en) 2022-09-08
JP2018030847A (ja) 2018-03-01
NZ616536A (en) 2015-10-30
JP6279905B2 (ja) 2018-02-14
LT2686002T (lt) 2018-05-10
EA201301024A1 (ru) 2014-03-31
IL228425A (en) 2017-08-31
KR102050339B1 (ko) 2019-11-29
CA2846786C (en) 2022-05-17
EA028448B1 (ru) 2017-11-30
US20250276042A1 (en) 2025-09-04
US20160101157A1 (en) 2016-04-14
EP2686002A1 (en) 2014-01-22
SG193446A1 (en) 2013-10-30
IL228425A0 (en) 2013-12-31
ES2666850T3 (es) 2018-05-08
AU2012229104A1 (en) 2013-10-03
US20170360890A1 (en) 2017-12-21
US9198955B2 (en) 2015-12-01
RS57175B1 (sr) 2018-07-31
KR20140038383A (ko) 2014-03-28
HUE036931T2 (hu) 2018-08-28
WO2012125809A1 (en) 2012-09-20
US10500254B2 (en) 2019-12-10
CN103702680A (zh) 2014-04-02
SI2686002T1 (en) 2018-06-29
NZ712273A (en) 2016-09-30
US20120237479A1 (en) 2012-09-20
HRP20180621T1 (hr) 2018-07-27
JP2014508174A (ja) 2014-04-03
PL2686002T3 (pl) 2018-10-31
SMT201800221T1 (it) 2018-07-17
EP2686002B1 (en) 2018-01-24
MX359947B (es) 2018-10-17
PT2686002T (pt) 2018-04-23
BR112013023609A8 (pt) 2018-04-03
CA2846786A1 (en) 2012-09-20
MX2013010507A (es) 2014-04-30
US20200046804A1 (en) 2020-02-13
JP6522069B2 (ja) 2019-05-29
AU2012229104B2 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
CY1122449T1 (el) Σχηματα δοσολογιας ανοσοσυζευγματος enanti-folr1
CY1119025T1 (el) Συνδυασμος δυο αντιιικων για την αγωγη της ηπατιτιδας c
CY1125628T1 (el) Συνθεση για τη θεραπεια του καρκινου
CY1120176T1 (el) Μεθοδος για τη μειωση των συμπτωματων που μοιαζουν με αυτα της γριπης που συνδεονται με ενδομυϊκη χορηγηση ιντερφερονης με τη χρηση ενος σχηματος κλιμακουμενης δοσολογιας ταχειας τιτλοδοτησης
BR112015026325A2 (pt) dosagem oral de compostos glp-1
CY1124532T1 (el) Δοσολογικα σχηματα για συζευγματα φαρμακου-αντισωματος αντι-tf
MX2015015735A (es) Regimenes de dosificacion de inmunoconjugado anti-receptor en folato 1 (folr1).
EA201590332A1 (ru) Фармацевтические комбинации, содержащие ингибитор b-raf, ингибитор egfr и, необязательно, ингибитор pi3k-альфа
HRP20180301T1 (hr) Postupci liječenja psorijaze uporabom il-17 antagonista
CY1115862T1 (el) Θεραπεια με πιρφενιδονη για ασθενεις με μη φυσιολογικη ηπατικη λειτουργια
MX368507B (es) Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-ctla-4 en la manufactura de un medicamento para el tratamiento de cáncer.
EA201491011A1 (ru) Способы лечения с помощью ингибитора гамма-интерферона
CR20140086A (es) Tratamientos de combinación para hepatitis c
MX2018005729A (es) Composiciones terapeuticas para tratamiento del virus de inmunodeficiencia humana.
MX388093B (es) Dosis y regimen para inhibidores de la interaccion hdm2-p53.
UY37861A (es) Agentes antivirales contra la hepatitis b
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
EA201791227A1 (ru) РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM
CY1123350T1 (el) Θεραπευτικα σχηματα καi μεθοδοι αντιμετωπισης σκληρυνσης κατα πλακας μεσω χρησης οφατουμουμαμπης
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
EP4424709A3 (en) Dosing regimen for anti-bcma agents
MY191506A (en) Dosage regimen for pegylated interferon
CY1121280T1 (el) Χρηση της θυαζολοπυριμιδινονης για τη θεραπεια της φλεγμονωδους νοσου του εντερου
CY1120669T1 (el) Συνδυαστικη θεραπεια για αγωγη σκληρυνσης κατα πλακας